Clinical Trials at Risk: Mitigating against Cyberattack

The last post in our risk management series discussed the relationship between issues and risks—namely, that a quality issue can elevate an existing risk or serve as a harbinger of a new risk. When an issue occurs, it’s not enough to react to the problem – we also need to anticipate the ripple effects.

Caleb Barlow, CEO of CynergisTek details in this article the COVID-19 pandemic increased risk of cyberattacks for clinical trial sponsors and vendors and describes how cyberattacks have evolved over the last several years, and why we should be preparing for one.

Click here to read the full story.

Previous Article
Security Validation and Why Should it be the New Mindset in 2021
Security Validation and Why Should it be the New Mindset in 2021

While the concept of security validation has been around for some time, at CynergisTek we recommend that se...

Next Article
Security Resilience in 2021 - Part 2
Security Resilience in 2021 - Part 2

David Finn, EVP of Strategic Innovations joins for part two of Security Resilience in 2021 to discuss cyber...